Novel lactam inhibitors of hepatitis C virus NS3 protease
申请人:——
公开号:US20030008828A1
公开(公告)日:2003-01-09
The present invention relates to lactams of Formula (I):
1
or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
&agr;-aminoboronic acids prepared by novel synthetic methods
申请人:Bristol-Myers Squibb Company
公开号:US06586615B1
公开(公告)日:2003-07-01
The present invention relates to a novel class of &agr;-aminoboronic acids of Formula (V),
which are useful as intermediates in synthetic processes for inhibitors of the serine proteases, leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin. More specifically, the &agr;-aminoboronic acids are useful as intermediates for the synthesis of Hepatitis C Virus (HCV) protease inhibitors. This invention also generally relates to novel methods for the preparation of &agr;-aminoboronic acids.